The short version of Research material fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-09. Anything still debated is marked as such rather than presented as settled.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
=== Communities === Scabies is endemic in many developing countries, and it tends to be particularly prevalent in rural and remote areas. In such settings, community-wide control strategies are required to reduce the rate of disease, as treatment of only individuals is ineffective due to the high rate of reinfection. Large-scale mass drug administration strategies may be required where coordinated interventions aim to treat whole communities in one concerted effort. Although such strategies have shown to be able to reduce the burden of scabies in these kinds of communities, debate remains about the best strategy to adopt, including the choice of drug. The resources required to implement such large-scale interventions in a cost-effective and sustainable way are significant. Furthermore, since endemic scabies is largely restricted to poor and remote areas, it is a public health issue that has not attracted much attention from policymakers and international donors.
The overall fold of the KaiA monomer is that of a four-helix bundle, which forms a dimer in the known structure. KaiA functions as a homodimer. Each monomer is composed of three functional domains: the N-terminal amplitude-amplifier domain, the central period-adjuster domain and the C-terminal clock-oscillator domain. The N-terminal domain of KaiA, from cyanobacteria, acts as a pseudo-receiver domain, but lacks the conserved aspartyl residue required for phosphotransfer in response regulators. The C-terminal domain is responsible for dimer formation, binding to KaiC, enhancing KaiC phosphorylation and generating the circadian oscillations. The KaiA protein from Anabaena sp. (strain PCC 7120) lacks the N-terminal CheY-like domain. KaiB adopts an alpha-beta meander motif and is found to be a dimer or a tetramer. KaiC belongs to a larger family of proteins; it performs autophosphorylation and acts as its own transcriptional repressor. It binds ATP.
Fast parallel proteolysis (FASTpp) is a method to determine the thermostability of proteins by measuring which fraction of protein resists rapid proteolytic digestion. Proteolysis is widely used in biochemistry and cell biology to probe protein structure. In "limited trypsin proteolysis", low amounts of protease digest both folded and unfolded protein but at largely different rates: unstructured proteins are cut more rapidly, while structured proteins are cut at a slower rate (sometimes by orders of magnitude). Recently, several other assays of protein stability based on proteolysis have been proposed, exploiting other proteases with high specificity for cleaving unfolded proteins. These include Pulse Proteolysis, Proteolytic Scanning Calorimetry and FASTpp.
The species A. maxima and A. platensis were once classified in the genus Spirulina. The common name, spirulina, refers to the dried biomass of A. platensis, which belongs to photosynthetic bacteria that cover the groups Cyanobacteria and Prochlorophyta. Scientifically, a distinction exists between spirulina and the genus Arthrospira, for which the two species were originally proposed. Species of Arthrospira have been isolated from alkaline brackish and saline waters in tropical and subtropical regions. Among the various species included in the genus Arthrospira, A. platensis is the most widely distributed and is mainly found in Africa, but also in Asia. The term "spirulina" (without italicizing and usually without capitalization) remains in use for historical reasons. In 2019 it was found that the cultivated species differ too much from the type species of Arthospira to be in the genus, necessitating another batch of renaming to Limnospira to reflect biological reality.
Thorium has been used as a power source on a prototype scale. The earliest thorium-based reactor was built at the Indian Point Energy Center located in Buchanan, New York, United States in 1962. China may be the first to have attempted to commercialise the technology. The country with the largest estimated reserves of thorium in the world is India, which has sparse reserves of uranium. In the 1950s, India targeted achieving energy independence with their three-stage nuclear power programme. In most countries, uranium was relatively abundant and the progress of thorium-based reactors was slow; in the 20th century, three reactors were built in India and twelve elsewhere. Large-scale research was begun in 1996 by the International Atomic Energy Agency to study the use of thorium reactors; a year later, the United States Department of Energy started their research. Alvin Radkowsky of Tel Aviv University in Israel was the head designer of Shippingport Atomic Power Station in Pennsylvania, the first American civilian reactor to breed thorium. He founded a consortium to develop thorium reactors, which included other laboratories: Raytheon Nuclear Inc. and Brookhaven National Laboratory in the United States, and the Kurchatov Institute in Russia. In the 21st century, thorium's potential for reducing nuclear proliferation and its waste characteristics led to renewed interest in the thorium fuel cycle. India has projected meeting as much as 30% of its electrical demands through thorium-based nuclear power by 2050.
Sources: en.wikipedia.org
== Medical uses == Insulin glargine/lixisenatide is approved as a prescription for adults with type 2 diabetes mellitus poorly controlled by lixisenatide or basal insulin alone. According to the American Diabetes Association, combination treatment of a GLP-1 receptor agonist with basal insulin should occur after HbA1C levels remain above target (7% for most type 2 people with diabetes) following use of basal insulin. The use of insulin glargine/lixisenatide and lixisenatide-containing products is not recommended for use while pregnant. There is insufficient data in humans to form a pregnancy risk category for lixisenatide. Animal pregnancy studies have shown potential risks to the prenate, but it is unclear if these risks are related to the drug. It is unknown if insulin glargine and lixisenatide are present in human milk or the effects these drugs would have on breastfed infants. Potential adverse effects to the mother and child as well as management of diabetes and glucose control should be considered prior to use of Soliqua during breastfeeding.
=== 2024 === During his 2024 campaign, polls generally showed that a majority of Americans believed that Trump was too old to serve as president. A February 2024 Ipsos poll finding that Joe Biden's age and health were major or moderate concerns for 86% of voters also found that 59% similarly thought Trump was too old to hold the office. During the course of the 2024 primary campaign, Trump made several gaffes, including confusing Nikki Haley for Nancy Pelosi, claiming he was running against Barack Obama (the Democratic candidate at the time was Joe Biden), and fearing the nation may enter World War II. A shift in Trump's speeches by 2024 towards shorter sentences, more tangents, more repetition, more all-or-nothing thinking, and more confusion of words and phrases could indicate cognitive decline. Basil Smikle of Columbia University argued in January 2024 that one reason Trump has not seen as much of the age criticism as Biden is that his rallies seem loud and vibrant, whereas Biden has a more old-school approach to politics. In January 2024, Jay Olshansky gave Donald Trump less than a 75% chance of living through a second term based on publicly available information about his health. Also in January 2024, red spots or sores were spotted on Donald Trump's hands. On June 14, 2024, Trump said that his longtime acquaintance Joan Rivers had told him that she had voted for him in the 2016 election, although Rivers had died in September 2014.
GcMAF (or Gc protein-derived macrophage activating factor) is a protein produced by modification of vitamin D-binding protein. It has been promoted as a treatment for various medical conditions, but claims of its benefits are not supported by evidence.
This differs from a case of constant extraction field where the ions are accelerated instantaneously upon being formed. Delayed extraction is used with MALDI or laser desorption/ionization (LDI) ion sources where the ions to be analyzed are produced in an expanding plume moving from the sample plate with a high speed (400–1000 m/s). Since the thickness of the ion packets arriving at the detector is important to mass resolution, on first inspection it can appear counter-intuitive to allow the ion plume to further expand before extraction. Delayed extraction is more of a compensation for the initial momentum of the ions: it provides the same arrival times at the detector for ions with the same mass-to-charge ratios but with different initial velocities. In delayed extraction of ions produced in vacuum, the ions that have lower momentum in the direction of extraction start to be accelerated at higher potential due to being further from the extraction plate when the extraction field is turned on. Conversely, those ions with greater forward momentum start to be accelerated at lower potential since they are closer to the extraction plate. At the exit from the acceleration region, the slower ions at the back of the plume will be accelerated to greater velocity than the initially faster ions at the front of the plume. So after delayed extraction, a group of ions that leaves the ion source earlier has lower velocity in the direction of the acceleration compared to some other group of ions that leaves the ion source later but with greater velocity.
== Technology == Flagler Global Logistics is using a new, proprietary, single-source, cold chain technology to attract more business from Latin and South American importers of perishable goods. Importers generally use colder northern ports, and then truck the products (which can include fruits, vegetables, and fresh-cut flowers) south in order to protect local farms against fruit flies and other pests. However, this circuitous supply chain route can contribute to large losses in products. Industry reports estimate that $35 billion in perishable foods are lost annually between farm and table, with nearly half of those losses due to in-transit temperature changes. FGL's new facility allows the company to employ a new cold chain process and treatment methods that can extend the shelf life of produce and other perishable items. In December 2013, the USDA approved the Logistics Center's treatment methods. Flagler Global Logistics President and CEO Chris Scott described the USDA approval as a “game-changer” in the industry, because it opens up Miami as a viable alternate distribution hub for Latin America exporters. Flagler Global Logistics also holds certifications from PrimusGFS (Global Food Safety Initiative scheme) and the FDA.
Sources: en.wikipedia.org
The Ms. Pat Show is an American television sitcom created by Jordan E. Cooper and Patricia "Ms. Pat" Williams that premiered on the streaming service BET+ on August 12, 2021. The show is based on the comedy and life story of comedian Ms. Pat as a convicted felon from the streets of Atlanta turned reluctant suburban mother. The series has received nominations for 4 Primetime Emmy Awards for Outstanding Directing for a Comedy Series.
==== Research and traditional medicine ==== Preliminary research indicates that the phytochemicals, betulin and possibly other triterpenes, are active in Episalvan gel and wound healing properties of birch bark. Over centuries, birch bark was used in traditional medicine practices by North American indigenous people for treating superficial wounds by applying bark directly to the skin. Splints made with birch bark were used as casts for broken limbs in the 16th century.
=== CD38 === CD38 is an enzyme that triggers inflammatory responses and type II CD38 contains an ecto-NADase or extracellular NADase, whereas type II CD38 contains an intracellular cADPR. CD38 consumes NAD, which can produce second messengers that help regulate immune activity. Cells that are programmed for cell death or apoptosis releases NAD+, and type II CD38 help recycle the extracellular NAD+ released from apoptosis, where both products of NADase, ADP-ribose and nicotinamide, can be used to resynthesize NAD+ via the NAD+ synthesis pathway. ADP-ribose must be converted to adenosine in order to enter the NAD+ synthesis pathway, where ADP-ribose first gets converted to AMP and then AMP gets converted to adenosine via non-classical adenosine generational pathway. The other product nicotinamide is membrane permeable, which allows the molecule to re-enter the NAD synthesis pathway more easily. CD38 NADase is also found in tissues and cells other than T cells, and CD38 is one of the main forms of NADase activity in mammals.
This system was firstly described in 1989 by Fields and Song using Saccharomyces cerevisiae as biological model. Yeast two hybrid allows the identification of pairwise PPIs (binary method) in vivo, in which the two proteins are tested for biophysically direct interaction. The Y2H is based on the functional reconstitution of the yeast transcription factor Gal4 and subsequent activation of a selective reporter such as His3. To test two proteins for interaction, two protein expression constructs are made: one protein (X) is fused to the Gal4 DNA-binding domain (DB) and a second protein (Y) is fused to the Gal4 activation domain (AD). In the assay, yeast cells are transformed with these constructs. Transcription of reporter genes does not occur unless bait (DB-X) and prey (AD-Y) interact with each other and form a functional Gal4 transcription factor. Thus, the interaction between proteins can be inferred by the presence of the products resultant of the reporter gene expression. In cases in which the reporter gene expresses enzymes that allow the yeast to synthesize essential amino acids or nucleotides, yeast growth under selective media conditions indicates that the two proteins tested are interacting. Recently, software to detect and prioritize protein interactions was published. Despite its usefulness, the yeast two-hybrid system has limitations. It uses yeast as main host system, which can be a problem when studying proteins that contain mammalian-specific post-translational modifications.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.